Koyfin Home > Directory > Health Care > Akebia Therapeutics > Preferred Equity

Akebia Therapeutics Preferred Equity Chart (AKBA)

Akebia Therapeutics annual/quarterly Preferred Equity from 2012 to 2013.
  • Akebia Therapeutics Preferred Equity for the quarter ending December 12, 2013 was $158m a 61.31% increase of 97m year over year
  • Akebia Therapeutics Preferred Equity for the last 12 months ending December 12, 2013 was $158m a 66.05% increase of 104m year over year
  • Akebia Therapeutics Annual Preferred Equity for 2013 was $158m a 61.31% increase of 97m from 2012
  • Akebia Therapeutics Annual Preferred Equity for 2012 was $61m a 12.24% increase of 7m from 2011
  • Akebia Therapeutics Annual Preferred Equity for 2011 was $54m
Other Balance Sheet Metrics:
  • Akebia Therapeutics Total Assets for the quarter ending December 12, 2018 was $997m a 55.57% increase of 554m year over year
  • Akebia Therapeutics Other Liabilities for the quarter ending December 12, 2018 was $95m a 0.76% increase of 1m year over year
  • Akebia Therapeutics Total Equity for the quarter ending December 12, 2018 was $143m a -38.27% decrease of -55m year over year
View Chart On Koyfin

Quarterly AKBA Preferred Equity Data

12/2013$158m
09/2013$155m
03/2013$61m
12/2012$61m

Annual AKBA Preferred Equity Data

2013$158m
2012$61m
2011$54m